Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer
Related Experiment Video
Updated: Jun 29, 2026
Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
M A Pantaleo1, M Nannini, A Maleddu
1Institute of Hematology and Medical Oncology L.A. Seragnoli, Sant'Orsola-Malpighi Hospital, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy. maria.pantaleo@unibo.it
Abstract:
The epidermal growth factor receptor (EGFr) is one of the most studied molecules as a target for cancer therapy. Over these last few years, several studies attempting to identify predictive biomarkers of treatment response, such as the receptor status or other molecules related to the downstream signalling pathway, have been conducted. However, from a clinical point of view, the information obtained from ex vivo analyses still has various limitations that may be overcome by the combination with molecular imaging technologies which may provide a noninvasive, global, in vivo evaluation of the molecular tumour background. The aim of this review is to report the preclinical results of all positron emission tomography (PET) tracers synthesized until now for in vivo detection of EGFr in cancer. Two classes of PET compounds have been developed: labelled small molecules such as tyrosine kinase inhibitors and labelled monoclonal antibodies. The in vitro and in vivo results of these PET tracers are very different depending on the chemical properties, positron emission radionuclide, or animal models. As a consequence, various critical questions are still open, and the implications of a translation in the clinical setting for EGFr imaging in cancer patients is discussed.
Insights
Positron emission tomography (PET) tracers show promise for in vivo imaging of epidermal growth factor receptor (EGFr) in cancer. Preclinical studies explore small molecules and antibodies, but clinical translation requires further research.
Area of Science:
- Oncology
- Molecular Imaging
- Radiochemistry
Background:
- Epidermal growth factor receptor (EGFr) is a key target in cancer therapy.
- Predictive biomarkers for EGFr-targeted treatments are crucial for clinical success.
- Ex vivo analyses have limitations; molecular imaging offers noninvasive in vivo evaluation.
Purpose of the Study:
- To review preclinical positron emission tomography (PET) tracers for in vivo EGFr detection in cancer.
- To evaluate the development of PET compounds targeting EGFr.
- To discuss the clinical implications of EGFr imaging in cancer patients.
Main Methods:
- Literature review of preclinical studies on PET tracers for EGFr.
- Categorization of tracers into small molecules (tyrosine kinase inhibitors) and monoclonal antibodies.
- Analysis of in vitro and in vivo performance of developed PET tracers.
Main Results:
- Two classes of PET tracers for EGFr imaging have been developed: small molecules and monoclonal antibodies.
- Significant variability exists in tracer performance based on chemical properties, radionuclide, and animal models.
- Preclinical data highlight challenges and potential for EGFr-targeted PET imaging.
Conclusions:
- PET imaging holds potential for noninvasive assessment of EGFr in cancer.
- Further research is needed to address open questions and optimize tracers for clinical translation.
- Successful clinical application of EGFr-targeted PET could improve patient selection and treatment monitoring.
